Novo Nordisk (NVO) Hit by Another Heart Drug Setback
Novo Nordisk ($NVO) has halted two late‑stage studies of its experimental heart drug ziltivekimab, marking a major setback in its push into cardiov...
Novo Nordisk A S (NVO)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 9,059,400 | $434,307,636 | -6% | 0.05% | |
| 2. | 8,831,400 | $423,377,316 | +13% | 0.05% | |
| 3. | Fisher Asset Management Ken Fisher | 8,324,948 | $399,098,057 | -8% | 0.12% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 8,270,785 | $396,501,433 | +6% | 0.18% |
| 5. | 5,087,000 | $243,870,780 | -13% | 0.12% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 20,397,110 | $977,837,453 | 0.51% | |
| 2. | 18,594,352 | $891,413,244 | 1.12% | |
| 3. | 13,041,109 | $625,190,796 | 0.14% | |
| 4. | 12,642 | $606,057,000 | 0.45% | |
| 5. | 12,009,200 | $575,721,048 | 0.04% |
News See All
Novo Nordisk Stock (NVO) Falls Despite Success in Children’s Weight-Loss Trial
Novo Nordisk’s ($NVO) shares in Copenhagen edged lower on Monday afternoon. This came even after the Danish pharma giant said in a statement that i...
Wegovy’s Latest Trial Gives Novo Nordisk (NVO) Another Potential Growth Catalyst
Novo Nordisk A/S (NYSE:NVO) has delivered encouraging late-stage data for Wegovy in younger children, with its STEP Young trial showing that 40.4% of children aged 6 to under 12 were no longer classified...
Pharma Giant Novo Nordisk Stock (NVO) Jumps Even as Deutsche Bank Repeats Sell Call
Shares of Novo Nordisk ($NVO) climbed by 4% to about $47 per share on Wednesday morning even after Deutsche Bank ($DB) reaffirmed its Sell rating o...
Wegovy’s German Debut Opens a New Front for Novo Nordisk (NVO)
Novo Nordisk A/S (NYSE:NVO) has launched its Wegovy weight-loss pill in Germany, making it the first country in the European Union where the oral version of the drug is available.
Eli Lilly Stock (LLY) Rattled as Companies Decline to Cover Weight-Loss Drug Costs
Some companies view obesity medications as optional treatments.
Is the Weight-Loss Drug Market Really a Winner-Take-All Fight Between Novo Nordisk (NVO) and Eli Lilly (LLY)?
On August 13, 2026, Novo Nordisk A/S (NYSE:NVO) CEO Mike Doustdar told Reuters that investors are underestimating how much the obesity drug market will fragment as new treatments arrive.
Eli Lilly (LLY) Is Suing Six Companies Over an Unapproved Drug—Leaving Novo Nordisk (NVO) Clear in the GLP-1 Wars
On August 12, 2026, Eli Lilly and Company (NYSE:LLY) said that it filed six lawsuits against US companies it accuses of illegally selling black-market versions of retatrutide.
Novo Nordisk Expands Its AI Push With AWS, But Can It Accelerate Drug Discovery?
Novo Nordisk A/S (NYSE:NVO) has entered a strategic partnership with Amazon Web Services to accelerate drug discovery and modernize its operations through artificial intelligence and cloud technology.
Hedge Fund Resource Center